FOLH1 and metastatic prostate carcinoma: Moreover, although VEE particles expressing the prostate-specific membrane antigen (PSMA) elicited strong immune responses in mice [91], only weak PSMA-specific immunogenicity was discovered in castration-resistant metastatic prostate cancer (CRPC) patients in phase I [92].